Royalty Pharma (RPRXN) Stock Statistics & Valuation Metrics
Total Valuation
Royalty Pharma has a market cap or net worth of MXN 719.49B. The enterprise value is MXN 42.30B.
- Market Cap
- MXN 719.49B
- Enterprise Value
- MXN 42.30B
Share Statistics
Royalty Pharma has 446,619,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 446,619,200
- Owned by Insiders
- 1.46%
- Owned by Institutions
- 38.34%
Financial Efficiency
Royalty Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.95%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 8.95%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 23.78M
- Profits Per Employee
- 7.71M
- Employee Count
- 100
- Asset Turnover
- 0.12
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Royalty Pharma is 27.60. Royalty Pharma’s PEG ratio is 8.04.
- PE Ratio
- 27.60
- PS Ratio
- 11.68
- PB Ratio
- 4.33
- Price to FCF
- 9.95
- Price to Operating Cash Flow
- 9.95
- PEG Ratio
- 8.04
Income Statement
In the last 12 months, Royalty Pharma had revenue of 2.38B and earned 770.95M in profits. Earnings per share was 2.33.
- Revenue
- 2.38B
- Gross Profit
- 2.38B
- Operating Income
- 1.56B
- Pretax Income
- 1.32B
- Net Income
- 770.95M
- EBITDA
- 1.64B
- Earnings Per Share (EPS)
- 2.33
Cash Flow
In the last 12 months, operating cash flow was 2.98B and capital expenditures 0, giving a free cash flow of 2.98B billion.
- Operating Cash Flow
- 2.98B
- Free Cash Flow
- 2.98B
- Free Cash Flow per Share
- 6.69
Dividends & Yields
Royalty Pharma pays an annual dividend of ―, resulting in a dividend yield of 1.33%
- Dividend Per Share
- ―
- Dividend Yield
- 1.33%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.05%
- Earnings Yield
- 2.75%
Stock Price Statistics
- Beta
- 0.15
- 52-Week Price Change
- 82.24%
- 50-Day Moving Average
- 1069.87
- 200-Day Moving Average
- 901.90
- Relative Strength Index (RSI)
- 67.24
- Average Volume (3m)
- 7,550
Important Dates
Royalty Pharma upcoming earnings date is Nov 04, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Financial Position
Royalty Pharma as a current ratio of 0.97, with Debt / Equity ratio of 138.20%
- Current Ratio
- 0.97
- Quick Ratio
- 0.97
- Debt to Market Cap
- 0.54
- Net Debt to EBITDA
- 5.09
- Interest Coverage Ratio
- 5.07
Taxes
In the past 12 months, Royalty Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Royalty Pharma EV to EBITDA ratio is 22.01, with an EV/FCF ratio of 12.69.
- EV to Sales
- 14.89
- EV to EBITDA
- 22.01
- EV to Free Cash Flow
- 12.69
- EV to Operating Cash Flow
- 12.69
Balance Sheet
Royalty Pharma has MXN 836.99M in cash and marketable securities with MXN 8.96B in debt, giving a net cash position of -MXN 8.12B billion.
- Cash & Marketable Securities
- MXN 836.99M
- Total Debt
- MXN 8.96B
- Net Cash
- -MXN 8.12B
- Net Cash Per Share
- -MXN 18.19
- Tangible Book Value Per Share
- MXN 19.91
Margins
Gross margin is 89.38%, with operating margin of 62.34%, and net profit margin of 32.15%.
- Gross Margin
- 89.38%
- Operating Margin
- 62.34%
- Pretax Margin
- 53.23%
- Net Profit Margin
- 32.15%
- EBITDA Margin
- 67.66%
- EBIT Margin
- 67.47%
Analyst Forecast
The average price target for Royalty Pharma is MXN 1,240.28, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- MXN 1,240.28
- Price Target Upside
- 2.20% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 0.03%
- EPS Growth Forecast
- -24.12%
Scores
- Smart Score
- 10
- AI Score
- ―
